Poster-Disease-modifying Therapy
October 25, 2021
Classic-MS: Long-Term Efficacy and Real-World Treatment Patterns for Patients with Relapsing Multiple Sclerosis Who Received Cladribine Tablets in Phase III Parent Trials
Background: CLASSIC-MS (NCT03961204) explores the long-term efficacy and durability of effect of cladribine tablets (CladT; cumulative dose...
Poster-Disease-modifying Therapy
October 25, 2021
Safety and Effectiveness of Peginterferon Beta-1a in a Subgroup of African American Patients: Plegridy Observational Program Interim Analysis
Background: Limited data on baseline (BL) characteristics and disease severity exist for Black/African American (AA) patients with multiple...
Poster-Disease-modifying Therapy
October 25, 2021
Comparable Ofatumumab Treatment Outcomes in Patients across Racial/Ethnic Groups in the Asclepios I/II and Apolitos Studies
Background: Ofatumumab is a fully human anti-CD20 monoclonal antibody approved by the FDA for treatment of adults with relapsing multiple...
Poster-Disease-modifying Therapy
October 25, 2021
Does Frequency and Severity of COVID-19 Differ By Disease Modifying Therapy in MS Patients?
Background: Some authors have reported positive associations between B-cell-depleting (anti-CD20) therapies and COVID-19 infection risk or...
Poster-Disease-modifying Therapy
October 25, 2021
Long-Term Efficacy and Safety of Eculizumab Monotherapy in AQP4+ Neuromyelitis Optica Spectrum Disorder
Background: In the randomized, double-blind, placebo-controlled, phase 3 PREVENT trial (NCT01892345), eculizumab was well tolerated and...
Poster-Disease-modifying Therapy
October 25, 2021
Acapella: B-Cell Repletion in Ocrelizumab-Treated Patients
Background: Ocrelizumab (OCR) is a humanized anti-CD20 monoclonal antibody approved for treatment of relapsing remitting (RRMS) and primary...
Poster-Disease-modifying Therapy
October 25, 2021
Baseline MRI Predictors of Cognitive Processing Speed in Participants with Secondary Progressive Multiple Sclerosis from the Phase 3 Expand Study
Background: Siponimod showed beneficial effects on magnetic resonance imaging (MRI) lesion activity, total brain and gray matter (GM)...
Poster-Disease-modifying Therapy
October 25, 2021
Is There Wearing Off with Ocrelizumab? Preliminary Results of Symptom Burden on Ocrelizumab, a Longitudinal Study (SymBOLS).
Background: Ocrelizumab (OCR), a humanized, anti-CD20 antibody therapy approved for multiple sclerosis (MS), is given at 6-month intervals....
Poster-Disease-modifying Therapy
October 25, 2021
Long-Term Effect of Siponimod on MRI Outcomes in Secondary Progressive Multiple Sclerosis: Analyses from the Expand Study up to 5 Years
Background: In the Phase 3 EXPAND core study, siponimod compared with placebo significantly reduced disability progression, cognitive...
Poster-Disease-modifying Therapy
October 25, 2021
Comparison of Therapy Selection Drivers within the S1P Receptor Modulator and Fumarate Classes Among Multiple Sclerosis Patients Who Recently Switched Treatment
Background: The number of disease-modifying therapies (DMTs) within the S1P receptor modulator and fumarate classes has expanded with...